GvHD: Advice for Patients
Experts share their insights and advice on how to best communicate with patients who are actively dealing with acute or chronic GvHD.
Future of Chronic GvHD
A look into the future of chronic GvHD and which treatment options patients the panel is most excited about.
Treatment Options: Steroid-Refractory GvHD
Experts define and review treatment options for patients with chronic GvHD that are also steroid refractory.
Treatment Options for Chronic GvHD
Comprehensive discussion into the available treatment options for patients that present with chronic GvHD.
Defining Chronic Graft vs Host Disease (GvHD)
Panel of oncologists define in chronic GvHD and review the typical presentation of a patient.
Novel Agents in Acute GvHD
Experts discuss new and exciting agents and combinations that are on the horizon for patients with acute GvHD.
Steroid Refractory Acute GvHD and REACH Trials
An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.
Acute GvHD: Clinical Presentation, Risk Factors and Treatment Options
Experts discuss the clinical presentation, grading system and review treatment options for patients with acute GvHD.
Future of Acute GvHD Prevention
A look into the future of acute GvHD prevention and discussing the impact of targeting specific organs to help manage GvHD prevention.
Clinical Implications of the Phase III BMT CTN 1703 Trial
Experts review the Phase III BMT CTN 1703 trial and share how the results of this trial might impact their practice and discuss the role of ATG and abatacept in their practice
Regimens Used for GvHD Prevention
A brief review of the different regimens used by experts for GvHD prevention at their institutions and discuss the importance of GvHD Prevention.
An Overview of Graft vs Host Disease (GvHD)
Expert oncologists define graft vs host disease (GvHD) and discuss which risk factors might increase a patient’s risk of developing GvHD.
Using Multidisciplinary Care to Optimize Outcomes in GVHD
Sharing closing thoughts on acute and chronic GVHD management, expert panelists first consider the value of multidisciplinary care.
Treatment Advances on the Horizon for Acute GVHD
Shifting their focus to acute graft versus host disease, panelists reflect on evolving treatment strategies and novel therapeutics.
Treatment Advances on the Horizon for Chronic GVHD
Expert panelists share their perspectives on ongoing treatment evolutions in the setting of chronic graft versus host disease.
Steroid-Refractory Chronic GVHD: Selecting and Sequencing Therapy
Following their review of available treatment for steroid refractory chronic GVHD, experts consider how they would optimally select and sequence therapy.
Treatment Armamentarium for Steroid-Refractory Chronic GVHD
Comprehensive discussion on each of the 3 standard-of-care treatment options for patients with steroid refractory chronic GVHD.
Frontline Treatment Strategies for Chronic GVHD
An overview of the frontline treatment armamentarium for patients diagnosed with chronic graft versus host disease.
Improving the Early Identification of Chronic Graft Versus Host Disease
Shifting their focus to chronic graft versus host disease, panelists emphasize the importance of early identification and diagnosis.
Identifying the Role of the Microbiome in HSCT and GVHD
Expert panelists review the role of the microbiome in the context of hematopoietic stem cell transplantation and steroid-refractory acute GVHD.
Steroid-Refractory GVHD: Enrolling Patients on Clinical Trials
Key opinion leaders highlight the value of clinical trials and share their perspective on enrolling patients in the setting of acute GVHD.
Overview of Therapy for Steroid-Refractory Acute Graft Versus Host Disease
Comprehensive discussion on the treatment options available for patients diagnosed with steroid-refractory acute GVHD.
What is the Role of Biomarker Testing in GVHD?
A brief review of the evolving utilization of biomarker testing in acute graft versus host disease, particularly for prognostic evaluation.
Challenges in Making a Diagnosis of Acute GVHD
Focusing on acute graft versus host disease, panelists consider tools and methods that help to overcome challenges in making a differential diagnosis.
Educating Patients and Caregivers on the Impact of Graft Versus Host Disease
Expert perspectives on how best to educate patients and caregivers on graft versus host disease symptoms and quality of life.
Graft Versus Host Disease: Optimizing Prophylaxis Techniques
Shared insight on standard-of-care prophylactic methods employed in the management of patients with graft versus host disease.
Understanding Pathophysiology and Risk of Graft Versus Host Disease
Expert panelists spearhead a discussion on the pathophysiology driving both acute and chronic graft versus host disease.
HSCT Approaches to Retain GVL While Preventing GVHD
Expert perspectives on novel transplantation strategies to prevent or improve outcomes in graft-versus-host disease.
Novel Targeted Agents in GVHD: The FLIGHT and AGAVE-201 Trials
Brief insight on the FLIGHT and AGAVE-201 trials in chronic GVHD, which analyzed itacitinib, a JAK inhibitor, and axatilimab, a CSF1R inhibitor, respectively.
Chronic GVHD: Novel Treatment Approaches With Approved Agents
Considerations for novel treatment approaches with approved agents in combination or the frontline setting of chronic graft-vs-host disease.
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis
Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma
Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD
2 Clarke Drive Cranbury, NJ 08512